Recruiting studies: Hepatocellular Carcinoma Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245 Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT05444478 Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Phase 2 · 12 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT07018947 Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150 A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573 TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
EARLY_Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT07242417 Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06454578 Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Phase N/A · 7 location(s) · Zhujiang Hospital · NCT06157060 Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NA · 1 location(s) · Sun Yat-sen University · NCT06609876 Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-R
Phase N/A · 1 location(s) · Tian'an Jiang · NCT06577272 Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Phase N/A · 1 location(s) · Tongji Hospital · NCT06653062 Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NA · 1 location(s) · Asan Medical Center · NCT06537193 Recurrent Liver Cancer: Reconceptualization and Reevaluation
Phase N/A · 1 location(s) · Nanjing Medical University · NCT06430983 HOPE Against Cancer Recurrence in HCC
Phase 4 · 37 location(s) · Philipp Dutkowski · NCT06717919 Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421 To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With H
Phase 1 · 2 location(s) · Shenzhen Xinhe Biomedical · NCT07594964 AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
Phase N/A · 1 location(s) · Tongji Hospital · NCT07062380 Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
NA · 1 location(s) · Beijing Hospital · NCT05738980 Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302 Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepato
Phase N/A · 1 location(s) · Zhujiang Hospital · NCT06861114 A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Phase 3 · 1 location(s) · Akeso · NCT05489289 Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06581315 Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepato
Phase N/A · 1 location(s) · University Hospital, Ghent · NCT05866783 Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04803318 Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Phase 1 · 1 location(s) · Hua Li · NCT05803928 The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06609850 Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT04615143 Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Phase 1/Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT05323201 Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
NA · 1 location(s) · University Hospital, Rouen · NCT05375370 Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Phase 1/Phase 2 · 1 location(s) · Tongji Hospital · NCT07282184

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.